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Fenofibric acid is a hypolipidemic agent that acts through PPARα and contributes to 
treatment of many types of dyslipidemias. It is the active metabolite of fenofibrate, 
but can be also administrated by itself. Concerning its metabolism, the majority of 
fenofibric acid is conjugated with glucuronic acid, while a minor amount yields a 
reduced metabolite. Reduced fenofibric acid is also an active substance. The identity 
of the enzymes participating in the reducing metabolic process has not been revealed 
yet. The current study investigated this carbonyl reduction in human liver subcellular 
fractions and by the use of nine recombinant cytosolic carbonyl-reducing enzymes of 
the AKR and SDR superfamilies. Enzymatic activity toward fenofibric acid reduction 
appeared in both cytosol and microsomes and was found that affinity of cytosol is 
greater while velocity in microsomes is higher. Of the nine tested enzymes, five 
reductases were identified to play role in the reduction of fenofibric acid. The highest 
activity was exhibited by CBR1, followed by AKR1C3, AKR1C2, AKR1C1 and 
AKR1B1. Our finding of significant contribution of microsomal fraction to the 
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kyseliny 
Fenofibrová kyselina je hypolipidemikum, které působí prostřednictvím PPARα, a 
používá se k léčbě různých typů dyslipidemií. Je to aktivní metabolit fenofibrátu, ale 
může být také podáván přímo. Co se týče metabolismu, většina fenofibrové kyseliny 
je konjugována s glukuronovou kyselinou zatímco malé množství je přeměněno na 
redukovaný metabolit. Redukovaná fenofibrová kyselina je také aktivní látka. 
Enzymy účastnící se tohoto redukčního metabolického procesu nebyly dosud 
identifikovány. Předkládaná studie zkoumala karbonylovou redukci v subcelulárních 
frakcích z lidských jater a za použití cytosolických karbonyl-redukujících enzymů 
z nadrodiny AKR a SDR. Enzymatickou aktivitu způsobující redukci fenofibrové 
kyseliny vykazoval jak cytosol tak mikrosomy a bylo zjištěno, že cytosol má větší 
afinitu zatímco rychlost redukce je větší v mikrosomech. Z devíti testovaných enzymů 
byla u pěti reduktas nalezena aktivita k redukci fenofibrové kyseliny. Největší aktivitu 
vykazoval CBR1 následován AKR1C3, AKR1C2, AKR1C1 a AKR1B1. Naše zjištění 
o významném přispění mikrosomální frakce ke karbonylové redukci fenofibrové 
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Fenofibric acid is the active metabolite of fenofibrate. It is a lipid-lowering drug that 
acts through the binding to nuclear peroxisome proliferator activated receptor alpha 
(PPARα). The activation of PPARα leads to the antihyperlipidemic effect through 
many pathways in the lipoprotein metabolism (Rang et al., 2012).  
Nowadays, WHO states the cardiovascular diseases as the number one cause of death 
in developed countries (2014). Although statins are thought to be the first line drug 
for this purpose, when they are combined with fibrates, the therapeutic results are 
more potent (Tenenbaum and Fisman, 2012; Saha et al., 2007). It is true that the 
combination of statins and fibrates can increase their common side effect of 
rhabdomyolysis, however, reports have shown that in case of use of fenofibric acids 
this is much lower (Jones and Davidson, 2007).  
It has also been shown that fibrates have a positive impact on reducing cardiovascular 
diseases, mainly by prevention of coronary artery disease (Jun et al., 2010). 
Moreover, it has been found that the prolonged therapy with fibrates lowers to a great 
degree the incidence on nonfatal myocardial infarction (Corsini et al., 2005; Saha et 
al., 2007). In 2009, the FIELD study has also presented the reducing effect of 
fenofibrate on microvascular complication of diabetes mellitus II (DM II), 
representing the superior positive action of fenofibrate in patients with metabolic 
syndrome (2005). The ACCORD-lipids study has also pointed this need especially for 
patients with DM II, increased triacylglycerols and low HDL (2010). Additionally, the 
predominant benefits were related to lowering of hypertriglyceridemia 
 
(FIELD study 
investigators, 2005; Krysiak, 2010). 
It is worth mentioning, that fenofibric acid do not exhibit many drug - drug 
interactions due the avoidance of the inhibition of CYP450 allowing it to be 
administrated in multitherapy. However, this does not concern all fibrate compounds 
in the same degree (e.g. gemfibrozil) but undoubtedly, fibrates are important and 
promising pharmaceutical compounds (Alagona, 2010). 
The mechanism of action of fibrates started to be understood in the beginning of 
1990s. However, less is known about their metabolism. Fenofibrate is hydrolyzed in 
the liver to the active form of fenofibric acid by esterases. The majority of the amount 




rest of fenofibric acid is firstly metabolized to reduced fenofibric acid, and then 
follows glucuronidation and excretion via urine. Moreover, in vivo studies have 
shown that the oxidative metabolism of fibrates and fenofibric acid does not occur at a 
remarkable level (Abbott Laboratories, 2010). On the contrary, no further information 





















2. THEORETICAL PART 
2.1  Metabolism 
Metabolism is the sum of chemical reactions and biological processes that occur in an 
organism and result in the modification of a molecule. It includes a variety of 
metabolic pathways. Each of them begins with an initial compound that after a 
cascade of reactions is transformed to its metabolite. Based on the result of this 
modification, the reaction may be anabolic or catabolic. 
Enzymes are required to catalyze the metabolic reactions. Enzymes can be found in 
many sites in the organism (e.g. cytosol, mitochondria, smooth and rough 
endoplasmic reticulum, peroxisomes), and their location within the cell facilitates 
ordered metabolism (Cambel and Reece, 2004). Eukaryotes use organelles to 
compartmentalize metabolic pathways allowing different metabolic chemical 
reactions to occur in specific location.  
The study of metabolism and various metabolic pathways can be accomplished in 
silico or/and by the use of pluripotent in vitro experimental methods (Testa et al., 
2012). In that way, it is possible to use liver preparations to examine the possible 
metabolic fate of the compounds, to compare the differences of transformation of 
compounds in different species and predict the corresponding metabolism in human 
body.  
 
2.2 Biotransformation of xenobiotics 
The term “xenobiotic” has its meaning in the Greek root of the word “xenos” ξένος, 
which means “stranger”. Apart from drugs, xenobiotic is any substance that is not 
native to the body, such as food, chemicals, pollutants etc. The study of xenobiotic 
biotransformation has been an interest topic since 1950s, and concerns many scientific 
fields, such as chemistry, biology, pharmacology and toxicology (Testa et al., 2012). 
Xenobiotics are usually characterized by high lipophilicity that enables them to 
penetrate membranes and other non-polar barriers, and at the same time they can 




decrease lipophilicity and increase hydrophilicity in order to allow the substances to 
be excreted by urine or bile (Coleman, 2005).  
During the biotransformation of a xenobiotic the produced metabolite may be the 
active compound, so we can call the process as activation or on the contrary, it can 
produce a less active derivate or not active at all, where it is called detoxification. 
Moreover, biotransformation allows us the production and use of prodrugs that can be 
metabolized to pharmacologically active compounds after reaching the target.  
If the biotransformation of a drug is not possible, its molecule would remain capable 
of crossing the barriers for longer time than acceptable, leading to accumulation of the 
active compound, hence a toxic and harmful result. A metabolite of a xenobiotic 
compound can also be a toxic compound. It is of major importance and concerning 
during the drug discovery and design the investigation of the metabolism of a 
compound that can lead to toxification (Testa et al., 2012).  
Biotransformation of xenobiotics is a biphasic process (Williams, 1959), known as 
phase I and phase II. The major organs that participate in these phases are liver, lungs 
and kidneys. An overview of the biotransformation phases of xenobiotics are 





Figure 1. The two phases of drug metabolism of a lipophilic compound  
Obtained from Wikipedia; https://encrypted-
tbn3.gstatic.com/images?q=tbn:ANd9GcSFeJjzRdXALv3ab4A-R8aU1gnaG6gX_oTauW-
cN10U_PdUFLDL1g.  
2.2.1 Phase I reactions 
The first phase of biotransformation is known as the functionalization. In this phase 
the purpose is to increase the polarity of the substances by addition or uncovering of a 
functional group. Most common are –COOH, -OH, -NH2 and –SH. The main 
reactions of this phase are hydrolysis, reduction, and oxidation catalyzed by the 









Table 1. Main phase I reactions, enzymes, and the location of action. 
 Adapted from Parkinson, 1996; Penner et al., n.d. 
Reaction Enzyme Localization 
Oxidation/ Reduction Cytochrome P450 Microsomes 
 Monoamine oxidase Mitochondria  
 Flavine monooxygenase Microsomes 
 Alcohol dehydrogenase Cytosol 
 Aldehyde dehydrogenase Cytosol, mitochondria 
 Aldehyde oxidase Cytosol 
 Xanthine oxidase Cytosol 
 Carbonyl reductases Cytosol, microsomes, blood 
 Nitro-reductase Microsomes, microflora 
 Azo-reductase Microsomes, microflora 
Hydrolysis Esterase Microsomes, cytosol, 
lysosomes, blood 
 Peptidase Blood, lysosomes 





The most common and known enzyme in phase I is the cytochrome P450 (CYP450). 
In fact, it is not a single enzyme, but a superfamily consisting of many subfamilies 
and enzymes that are responsible for the majority of the xenobiotic biotransformation 
(Nelson, 2004; Guengerich, 2008;
 
Zanger & Turpeinen, 2008; Zanger & Schwad, 
2013). Almost 60% of the drugs today are metabolized by isoforms of CYP family 
(Testa, 2012). 
Apart of the phase I enzymes, another component required for biotransformation is 
often a co-factor. In most cases it is nicotinamide adenine dinucleotide or 
nicotinamide adenine dinucleotide phosphate (NAD(P)
+
or NAD(P)H). These 
compounds are electron carries and therefore, enable the electron transfer. 
Reductive metabolism and especially carbonyl reducing enzymes will be discussed in 
chapter 2.3.1. 
2.2.2 Phase II reactions 
The second part of the biotransformation is known as conjugation reactions. It is an 
anabolic stage where the formed compound of phase I accepts a substituent group that 
transforms it into an inactive compound. This conjugation results in attachment of 
small, polar and ionizable endogenous molecules to phase I product, or to the parent 
drug itself, resulting in more hydrophilic compounds ready for excretion. 
Predominant organ of phase II is liver and the main enzymes of this phase are mainly 





Table 2. Main biotransformation reaction phase I, xeno-enzymes, and the location of action. 
Adapted from (Parkinson, 1996; Penner et al., n.d.) 
Reaction Enzyme Localization 
Conjugation Uridine diphosphoglucuronosyl 
transferase 
Microsomes 
 Sulfotransferase Cytosol 
 Methyl transferase Cytosol, microsomes 
 N-acetyl transferase Cytosol, mitochondria 
 Amino acid conjugation enzyme Mitochondria, Microsomes 
 Glutathione S-transferase Cytoplasm 
 
All of these reactions require, apart from the enzyme, a high energy molecule, such as 
glucuronic acid and glutathione, that are attached on an electron rich atom of the 
substrate (i.e. O, S, N). 
All of the transferases, have a wide spectrum of binding, that enables them to be 





2.3 Reductive metabolism 
The reductive pathway of the phase I of the biotransformation can occur when 
compounds contain carbonyl, azo or nitro groups. Other compounds that can undergo 
reduction are epoxides, halogenated hydrocarbons and heterocyclic ring compounds. 
During reduction, carbonyl groups are reduced to alcohols, while azo and nitro group 
to respectively amino derivatives. Since these reactions are reductive, a source of 
electrons is required. In most cases, NAD(P)H holds this role (Gibson and Skett, 
2001). Reduction is less common metabolic reaction in human living cells than 
oxidation. 
 
2.3.1 Carbonyl reduction 
This part concerns in detail the carbonyl reduction, and the enzymes that participate in 
this process. Xenobiotic compounds are reduced at the carbonyl moiety of their 
molecule. Carbonyl group is a group where a carbon atom is double-bonded to an 
oxygen atom: -C=O. Compounds that have this bond in their structure are aldehydes 
(RCHO), ketones (RCOR`), carboxylic acids (RCOOH), esters (RCOOR`), amides 
(RCONR`R``) and quinones. Carbonyl groups can be found in acyclic, aromatic, or 
aliphatic molecules.  
The bond between oxygen and carbon is covalent but the difference of 
electronegativity between these atoms allows oxygen to be slightly negatively 
charged. This is what attracts H
+
, an electrophile ion, to be attached to oxygen, thus 
reducing it.  
In case of reduction of asymmetrical ketone compound to secondary alcohol the result 
is the creation of a chiral centre, thus the formation of enantiomers. In such cases, it is 
demanding determine the configuration of the metabolites, along with examination of 
enzyme stereospecificity (Skarydova and Wsol, 2012). 
Because a reduction reaction may be the opposite of the oxidation reaction, both 
reactions are sometimes catalyzed by the same enzyme. For example, reduction of 
many aldehydes and ketones to primary and secondary alcohols, respectively, and the 
opposite reaction, oxidation, is catalyzed by the enzyme alcohol dehydrogenase 




cytosolic enzyme that exists predominantly in liver cells. In human species, it has 
been found that there are approximately nine different isoenzymes of alcohol 
dehydrogenase, which are encoded by seven different genes (Davis et al., 1996). The 
oxidation reaction with alcohol dehydrogenase requires the reduction of the co-factor 
NAD
+
. Carbonyl reduction, similarly as other phase I reactions, may result in either 
bioactivation or detoxification of initial compound (Hoffman and Maser, 2007). 
Studies have shown evidence for cases as activation of the drug (e.g. warfarin) or of 
the prodrug (e.g. propanolol), detoxification (e.g. quinine) or even toxification (e.g. 
daunorubicin) (Maser, 1995). 
 
2.3.2 Carbonyl-reducing enzymes 
Although the participation of carbonyl-reducing enzymes (CREs) in phase I 
metabolism was first mentioned in 1980s it is still largely undescribed
 
 (Oppermann & 
Maser, 2000). The existence of CREs has been found not only in humans, but in many 
other species of animals and plants, so they are ubiquitous. 
Main CREs can be divided into two superfamilies, according to their protein 
structure; the aldo-keto reductases (AKR) and short-chain dehydrogenase reductase 
(SDR) superfamily. Recent development of genetic has allowed investigating these 
enzymes and starting to understand their influence on metabolism of drugs.  
Recently, a review has been published about drugs metabolized by carbonyl-reducing 
enzymes. The drugs were divided in three groups, as shown in Table 3, according to 
the degree of knowledge about their metabolism by CREs. Additionally information 
of this table attached separately, are xenobiotics that have already been presented in 









Table 3. Drugs undergoing carbonyl reduction. Adapted from Malatkova and Wsol, 2014 
Group 1 Group 2 Group 3 Barski at al. (2008) 
Benfluron Nabumetone Fenofibrate/ Acetohexamide Loxoprofen 
Dimefluron Bupropion Fenofibric acid Befunolol Nafimidone 
Boceprevir Methylnatrexone Naftazone Daunorubicin Naloxone 
Glucocorticoids Eperisone Pentoxyfylline Dolasetron Naltrexone 
Tibolone Tolperisone Oxcarbazepine Doxorubicin Oracin 





Wortmannin Metyrapone  Haloperidol S-1360 
   Ketoprofen Timiperone 
   Ketotifen  
 
Within contrast to CYP450 that exists only in microsomes, CREs do exist in both 
cytosol and microsomes. However, the cytosolic forms of CREs are much more 
known and investigated than the microsomal ones (Skarydova and Wsol, 2012). 
 
2.3.2.1 Aldo-keto reductase superfamily 
AKR is the biggest superfamily of NAD(P)(H) – dependent oxidoreductases in 
humans. This superfamily contains more than 190 members divided into 19 families. 
In humans have been found around 15 enzymes so far (Penning, 2015). 
The enzymes form AKR superfamily have common protein structure. Their structural 
fold called (α/β)8 barrel consists of 8 parallel α-helixes that are external and include 
the 8 parallel β-strands. It is also called as TIM-barrel fold on the basis of the 
structure of triose-phosphate isomerase enzyme. Conserved sequence of amino acids 
that is required for the oxidation of NAD(P)H is Asp-Tyr-Lys-His. Tyrosine 
conserved residue is thought to play the most important role in the acid-base catalytic 
action of these enzymes. Many variations exist in either α-helixes, β-strands or the 




superfamily as well as the differentiation of human AKRs from other mammalians 
AKRs (Barski et al., 2008). The reaction that AKRs catalyze has bi-bi ordered 
mechanism, meaning that there are two reactants and two products, where the cofactor 
needs to be bounded first to initiate the reduction and is unbound after termination of 
the reaction (Oppermann and Maser, 2000; Barski et al., 2008). 
Another characteristic of AKRs is their gene polymorphisms. Gene polymorphisms 
occur either in coding, or in most cases in non-coding parts of these genes. The 
diversity of variants of particular gene influences the enzymatic activity in 
biotransformation of xenobiotics, but may be also involved in disease induction (Jin 
and Penning, 2007). 
Mammalian members of this superfamily are active as monomers and predominate in 
cytosol. They act as aldehyde reductase, aldose reductase, and dihydrodiol 
dehydrogenase (Opermann and Maser, 2000; Mindnich and Penning, 2009). 
Nomenclature of AKRs has been used the last 12 years. It follows the common 
system for naming enzymes, as well as in case of CYP enzymatic superfamily. The 
first three letters of all the enzymes are AKR meaning Aldo-Keto Reductases, 
defining the enzymatic catalytic reducing activity on aldehydes and ketones. Next to 
this prefix is a number of arabic system corresponding the family, then another capital 
letter representing the subfamily; A for aldehyde reductases, B for aldose reductases 
and C for hydroxysteroid dehydrogenases. In the end, a number for the respectively 
sequence of the one and only enzymes. Details and historical information are found in 
the database of the University of Pennsylvania in the following link: 
http://www.med.upenn.edu/akr/nomenclature.shtml. Figure 2 presents members of 





Figure 2. Phylogenetic tree of human AKRs enzymes. Adapted from Barski et al, 2008. 
 
Another enzyme database system that participates in nomenclature of enzymes is 
BRENDA, found at www.brenda-enzymes.org. This scientific page provides a lot of 
information for the most enzymes, along with the Enzyme Commission (EC) number. 
EC number is a short numerical sequence based on the chemical reaction of any 
enzyme that is able to catalyze. 
The ability of studying the enzymatic action of AKRs enzymes in vitro, is facilitated 






Aldehyde reductase (AKR1A1, EC 1.1.1.2) is a cytosolic NADPH dependent 
reducing enzyme. It is one of the first AKRs that have been described, in concrete in 
1961 in rat liver (Barski et al., 2008). It has been also found that AKR1A1 exist in 
other mammals, except humans and rodents. 
The reducing catalytic activity of aldehyde reductase favors carboxyl group in 
substrates that are negatively charged, even though its wide spectrum of activity allow 
also aromatic, steroid and smaller aldehydes to be desirable substrates for AKR1A1 
(Barski et al., 2008).  
The prior importance of AKR1A1 has been found in the anabolism of ascorbic acid, 
where in the rodents is its participation essential. In humans, it is also the reducing 
enzyme of D-glyceraldehyde to glycerol and of melvadate towards the regulatorof 
cholesterol synthesis and triglycerides, mevalonic acid. 
Concerning the action in a drug metabolism, it has been yet found only the role of 
AKR1A1 in reduction of antitumor agent doxorubicin to cardiotoxic metabolite 
doxorubicinol (Mindnich and Penning, 2009). 
 
Aldose reductases 
There are two members of the subfamily AKR1B; aldose reductase AKR1B1 (EC 
1.1.1.21), and the small intestine aldose reductase AKR1B10 (EC 1.1.1.21). Both 
proteins are cytosolic NADPH dependent reductases.  
AKR1B1 is the rate-limiting enzyme in the polyol pathway, where it reduces glucose 
to sorbitol, which makes this protein involved in pathogenesis of diabetes mellitus. 
Hence, up-regulation of this enzyme, leads to sorbitol accumulation. This information 
has led to use aldose reductase inhibitors for either prevention or treatment of 
hyperglycemic complication (Liu et al., 2009). While in animals studies diabetic 
retinopathy was related to AKR1B1, this has not been confirmed in humans (Abhary 




It was also found that many fibrate agents inhibit AKR1B1 in both directions of its 
redox actions. In particular, fenofibrate show in reduction direction pure non-
competitive inhibition, and in oxidation direction competitive inhibition. Among all 
fibrates, fenofibrate was more effective in inhibiting aldose reductase action. This set 
the question how AKR1B1 can influence the metabolic processes of fibrates 
(Belendiran and Rajkumar, 2005). Moreover, AKR1B1, as well as AKR1A1, 
participates in the metabolism of lipid aldehydes (Penning and Drury, 2007).  
Another drug, where AKR1B1 participates in the biotransformation, is cytotoxic 
cyclophosphamide. In reality, AKR1B1 catalyzes the reduction of 
cyclophosphamide’s metabolite produced by CYP450, acrolein, that is responsible for 
the unwanted side effects of the chemotherapeutic therapy. Reduction of acrolein 
leads to minimization of hemorrhagic cystitis (Jin and Penning, 2007). 
AKR1B10, is also an aldose oxidative sensitive protein, and is from 70% identical to 
the amino acid sequence of AKR1B1 (Cao et al., 1998). It is mainly expressed in 
intestine and colon cells, and so is called small intestine aldose reductase. 
AKR1B10 has been suspected for existence of many mutations and pseudogenes. In 
particular, investigation of the influence of mutations of AKR1B10 on inhibition 
action by fibrates showed that reduced metabolite of fenofibric acid is less potent than 
fenofibrate, while it is the only that can induce pure non-competitive inhibition 
against DL-glyceraldehydes reduction. On the contrary, fenofibrate demonstrates 
mixed non-competitive inhibition at the reducing action of AKR1B10 in this reaction 
(Balendiran et al., 2009). 
Both aldose reductases have been target for modern approaches for anticancer 
therapies, since it is stated that their overexpression is related to many tumors, such as 
lung, breast, and colon tumors among others (Ramana and Srivastava, 2010). The 
decrease expression of AKR1B10 genes can be used as a diagnostic tool for colorectal 
cancer (Kropotova et al., 2009). Another common feature of AKR1B10 and 








Four members of the subfamily of hydroxysteroid dehydrogenases; AKR1C1 (EC 
1.1.1.149), AKR1C2 (EC 1.1.1.213), AKR1C3 (EC 1.1.1.188) and AKR1C4 (EC 
1.1.1.50); share over 80% homology in their genes (Chen and Zhang, 2012). They 
were named based on their participation in metabolism of steroid hormones, 
catalyzing their oxidation –reduction transformations. AKR1C4 exist almost only in 
liver, demonstrates the highest catalytic activity (Barski et al., 2008). Moreover, 
AKR1C1, AKR1C2 and AKR1C3 enhance progesterone metabolism (Hevir et al., 
2011). AKR1C3 is in addition involved in the metabolism of prostaglandins, while 
AKR1C4 of bile acids (Barski et al., 2008). All of them participate in metabolism of 
xenobiotics, and are important in pathogenesis of many human diseases, especially 
cancers (Oppermann, 2007; Jin and Penning, 2007; Barski et al., 2008; Jin, 2013; Yun 
et al., 2015). 
All of the enzymes of this subfamily share the reduction activity toward aldehydes 
and ketones to respectively primary and secondary alcohols, and the presence of 
NAD(P)H as cofactor. They are soluble proteins present in cytosol and active as 
monomers (Barski et al., 2008). 
AKR1C1 activity has been studied in the metabolism of anticancer drugs, as the 
detoxification of cisplatin, and metabolism of methotrexate. The up-regulation of 
AKR1C3 protein was related to drug resistance to these drugs (Selga et al., 2008). 
Additionally, potential chemotherapeutic drug oracin is also reduced to both of its 
enantiomers by AKR1C enzymes. But, only AKR1C1 is able for the reduction to both 
of these isomers, while AKR1C2 and AKR1C4 only for one of them (Wsol et al., 
2007). Befunolol, an antihypertensive agent, is another substrate for AKR1C1 and 
AR1C2 (Barski et al., 2008). 
The first three isoforms of this subfamily of oxidoreductases (AKR1C1-C3), 
accompany the action of AKR1A1 and AKR1B1 in the detoxification of lipid 
aldehydes, PUFA’s peroxidation products, that are involved then in to the expression 
of neurodegenerative diseases. Among all AKR1C enzymes, AKR1C1, showed the 
highest catalytic efficiency (Penning and Drury, 2007). Other common substrates of 
AKR1C isoforms is the antidepressant but also smoking cessation alleviating agent 




AKR1C3 regulation seems to be directly influenced by interleukin-6. Moreover, 
catalytic action of this enzyme is associated with cancers such as breast and prostate 
(Penning, 2015). Apart from the diseases, it also affects the chemotherapeutic 
resistance to methotrexate (Zhao, 2014). 
Concerning the reducing catalytic activity of AKR1C3 toward xenobiotics it seems 
that in most cases it is not detected, apart from some neurological agents, such as 
naloxone, naltrexone, haloperidol and timiperone (Barksi et al., 2008). 
Both AKR1C2 and AKR1C4 participate in the major metabolic pathway of the 
NSAID drug loxoprofen. On the contrary, reduction of ketoprofen is not the major 
metabolic pathway, but again AKRs participate in this reaction (Ohara et al., 1995). 
As well, oxcarbazepine is sufficiently reduced by all four isoforms of the human 
AKRs (Malatkova et al., 2014). 
Another substrate of AKR1C1, AKR1C2, and AKR1C4 is nitrosamine 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NKK), a harmful constituent of 
tobacco. While the product of NNK metabolism by CYP450 is a tobacco-related 
cancer substance, the detoxification by those AKRs allows its glucuronosylation and 
excretion (Atalla et al., 2000).  
 
2.3.2.2 Short-chain dehydrogenase/reductase superfamily 
The second major superfamily of reducing enzymes is the short-chain dehydrogenase/ 
reductase superfamily. This superfamily counts more than 46000 members with great 
function diversity. Along with AKRs, they are considered to be the main enzymes 
catalyzing the oxidation – reduction reaction in a xenobiotics with carbonyl group 
(Hoffmann and Maser, 2007; Skarydova and Wsol, 2012). Nomenclature of those 
proteins was established, and more information is available on http://www.sdr-
enzymes.org./. 
SDRs are able to catalyze the reduction of aldehydes and ketones to respectively 
alcohols similarly to several AKRs. Those enzymes are NAD(P)H dependent 
oxidoreductases, while there have been favoring NADPH (Barski et al., 2008). 
Typical structure motif is Rossmann fold consisting of 6 parallel β-strands linked to 




sequence Asn-Ser-Tyr-Lys, but it is the conserved Tyr amino acid that is responsible 
for the catalytic action. The reaction mechanism is bi-bi ordered (Oppermann et al., 
1997). The majority of these superfamily members are either homodimers or 
homotetramers, but some exists also as monomers. SDRs are found as reductases and 
dehydrogenases (Hoffamnn and Maser, 2007; Skarydova and Wsol, 2012).  
SDRs are involved in the metabolism of many endogenous and xenobiotic 
compounds, thus they can be located in many places within the cell, such as cytosol, 
microsomes, and mitochondria. 11β-Hydrosteroid dehydrogenase (11β-HSD) is a 
dimeric microsomal enzyme, and the most known of this superfamily. It consists of 
two isoforms, 11β-HSD1 and 11β-HSD2. Excellent substrates for 11β-HSDs are 
glucocorticosteroids and sex hormones along with their precursors (Skarydova 
andWsol, 2012). However, only 11β-HSD1 in involved in biotransformation of 
xenobiotics. Metyrapone, oracin and NKK are some of its favorable substrates 
(Malatkova and Wsol, 2013). 
Several SDRs have another biological function apart from their enzymatic activity, a 
non-catalytic property. These multifunctional proteins are known as “moonlighting 
proteins”. The multitasking activity of SDRs point to additional importance of those 
enzymes and give motivation for further research on CREs from this superfamily 
(Ebert et al., 2014). 
Humans have been found to express three genes of cytosolic carbonyl reductases 




CBR1 (EC 1.1.1.184) is a cytosolic monomeric enzyme of SDR superfamily, and it is 
widely distributed in human tissues (Maser and Hoffmann, 2007). An unusual and 
interesting characteristic of this enzyme, is that in vivo can be found in three slightly 
different forms, as a result of positional modification in Lys residue (Maser and 




Favorable endogenous substrates for CBR1 seem to be mainly quinones, 
prostaglandins and tetrahydrobiopterin, making this enzyme important in plenty of 
biochemical pathways (Malatkova et al., 2010). Quinones, either as endogenous or 
xenobiotic compounds are detoxified in two possible ways; one- and two-electron 
reduction, and in both cases CBR1 is the enzyme of major importance (Malatkova et 
al., 2010). 
Besides AKRs reduction of NKK, as written previously, it is also CBR1 that 
detoxifies this compound, and in fact results in a more efficient biotransformation 
(Atalla et al., 2000). Alike, oxcarbazepine reduction metabolism by both CBR1 and 
CBR3 has showed interesting results in vitro but not further information for in vivo 
action is yet known (Malatkova et al., 2014). Benfluron, dimefluron, and wortmamnin 
have already shown evidence for carbonyl reduction by CBR1, while nabumetone not 
surely yet (Malatkova and Wsol, 2014). Flavonoids, menadion, indomethacin have 
been mentioned as inhibitors of CBR1 (Gonzalez-Covarrubias et al., 2008; Malatkova 
et al., 2010). 
CBR1 and CBR3, concerning their sequences are very similar, but their activity differ 
a lot, since it is only CBR1 that is of high importance in reducing metabolism of 
endogenous and xenobiotic compounds (Malatkova et al., 2010). As a matter of fact, 
CBR3 a monomeric reductases, has not so far appear any significant catalytic activity, 
except for ortho-quinones and menadione
 
(Hoffmann and Maser, 2007; Malatkova et 
al., 2010). CBR4 is sharing gene similarity with both CBR1 and CBR3 up to 23% and 
22% respectively, but has not been mentioned to be involved in xenobiotic 





2.4 Carbonyl reduction in cytosol vs. in microsomes 
Concerning metabolism, the two quantitatively most important subcellular 
localization are microsomes (endoplasmic reticulum) and cytosol. Different enzymes 
are present in either one or the other locations.  
Liver microsomes are the metabolic active subcellular fraction of endoplasmic 
reticulum, and exists primarily as vesicles. Microsomal enzymes constitute the 
majority of oxidoreductases (e.g. CYP450, flavin containing monooxygenase), 
hydrolases, and so predominate in phase I of biotransformation reaction. Additionally, 
in microsomes can be found some enzymes that participate in phase II reactions, as 
uridine diphosphate-glucuronosyltransferase, methyl-transferase etc. 
Cytosol is the soluble fraction of cytoplasm, and consists of many water-soluble 
enzymes. The enzymes found in cytosolic fraction, include hydrolases, AKRs and 
most of the conjugating enzymes, as glucuronidases, transferases, sulfotransferases 
etc., thus predominate in phase II reactions.  
On the other hand, in phase II reaction, it is only one microsomal enzyme known, 
UDP-glucuronosyltransferase (UGT). UGT and its isoforms occur in microsomes, but 
they are participating in many biotransformation reactions. 
Nevertheless, microsomal enzymes tend to be an important and promising part of the 
metabolism of both endogenous and exogenous compounds. However, there is a lot of 
information missing about microsomal enzymes, including microsomal carbonyl- 





2.5 Fenofibric acid  
Fenofibric acid (ABT 225) or according to its IUPAC name 2-[4-(4-
chlorobenzoyl)phenoxy]-2-methylpropanoic acid is an antihyperlipidemic agent that 
is available in the market by many trade names in both delayed release capsules and 
tablets. In fact, the isopropyl ester of fenofibrate is available since 1976 and releases 
the active metabolite fenofibric acid. Lately, in the USA fenofibric has become also 
available in form of choline salt, under the trade name Trilipix©, by Abbott. 
 
2.5.1 Pharmacological action 
Mechanism of action of fenofibric acid can be characterized as pleiotropic, since this 
agent is able to influence metabolic processes in many ways. 
Fenofibric acid acts by activation of peroxisome proliferator-activated receptors 
(PPARs). Three nuclear receptors have already been identified PPARα, PPARβ and 
PPARγ. Fenofibric acid is an agonist of PPARα that is found extensively in liver, 
muscle, kidney and heart, and can influence fatty acids degradation via β-oxidation in 
both peroxisomes and mitochondria. When PPARα is activated, its transcriptional 
activity is enhanced and results in expression of genes that are involved in lipoprotein 
metabolism and consequently lead to elevation of “good” high density lipoprotein 
(HDL). Moreover, this nuclear receptor affects many proteins and enzymes that are 
fat-regulating leading to reduced triacylglycerides by lower fatty acid synthesis and 
parallel increase of cellular uptake of fatty acids. Taken together, it is achieved 
increase of HDL (↑ 12-25%), and decrease of triacylglycerides (↓35-50%), LDL and 
total cholesterol (Chinetti et al., 2001; Kelly, 2001; Barbier et al., 2002; Tojcic et al., 
2009). 
Beyond the hypolipidemic effects of fenofibric acid, the activation of PPAR 
transcription factors, results in a cardioprotective and anti-inflammatory action due to 
prevention of atherosclerosis, decrease of the level of fibrinogen and elevation of C-
reactive protein (Tziomalos and Athyros, 2006; Balakumar et al., 2011). Additionally, 
it is introduced in the therapy of patients with metabolic syndrome with 
accompanying dislipidemia and insulin resistance because it provides beneficial 





2.5.2 Clinical uses 
The pleiotropic effect of fenofibric acid provides the agent a wide spectrum of 
activity. It is a well-tolerated agent that can be used in monopharmacotherapy 
(Keating, 2011). First of all, it is used in mixed dyslipidemias, where we have to face 
both increased triglyceride and cholesterol serum levels. In same way, it is a safe 
option when this situation is accompanied by hyperuricemia (Rang et al., 2012). 
Furthermore, it is indicated in primary hypertriglyceridemia as a first line agent, and 
in less common type III dysbetalipoproteinemia (Staels et al., 1998). Of greatest 
interest is the indication in patients of metabolic syndrome with DMII, where the level 
of HDL is usually decreased. Additionally, the ACCORD-lipid study added evidence 
of an improvement in retinopathy of diabetic patients (ACCORD study group, 2001; 
MacKeage and Keating 2011). FIELD trial also mentioned the decrease in 
microvascular complications and the prevention role in non-fatal myocardial 
infarction (FIELD study investigators, 2005; Tziomalos and Athyros, 2006).Worth 
saying is that fenofibric acid, in contrary to other fibrates derivatives, is the only agent 
that has been approved for combination with HMG-CoA reductase inhibitors (statins) 
(Yang and Keating, 2009). This combination minimizes the complications of the other 
common combined therapy, muscle pain and myositis. 
 
2.5.3 Metabolism 
Both in case of prodrug fenofibrate, that requires first to be hydrolyzed in intestine to 
reveal the active metabolite, and in other, when fenofibric acid is administrated as 
choline salt and dissociation occurs in gastrointestinal track, the available 
administration is only per os. Concerning its distribution, once fenofibric acid enters 
the blood stream it is bounded to albumin in order to get to its target, PPARα.  
Biotransformation takes place in the liver and kidneys. Fenofibric acid is able to be 
glucuronosylated immediately, before being reduced to its metabolite, and been 
detoxified (Chapman, 1987). In vitro study of the glucuronidation of fenofibric acid 
by recombinant isoforms of UGTs and liver microsomes, showed that this reaction 
can be performed by many isoforms of hepatic UGTs, but UGT2B7 and UGT1A9 
holds the greatest role, followed by lower affinity for UGT1A3 and UGT1A6. 




variability among individuals, probably due to genetic factors (Gonzales-Covarrubias 
et al., 2008). 
Reduced fenofibric acid, is the active product of the reduction of fenofibric acid. 
According to molecular structure of fenofibric acid, it is clear that the compound is 
reduced at the ketone moiety. An article published by FDA about available 
fenofibrate agents that are metabolized in liver and small intestine to fenofibric acid 
declares that: “In vivo metabolism data indicate that neither fenofibrate nor fenofibric 
acid undergo oxidative metabolism (e.g., CYP450) to a significant extent” (2008). 
Moreover, it is known that only 5% avoids the glucuronidation and undergo reduction 
(Chapman, 1987). On the contrary, the reductive product of fenofibric acid 
predominates in the biotransformation in rats and dogs (Caldwell, 1989). Additional 
in vivo study with rat hepatocytes has found apart from reduced fenofibric acid a 
small amount of another product due to methylation of fenofibric acid (Cornu-
Chagnon et al., 1995). Noteworthy, no enzyme has been identified to date that is 
responsible for the reduction of fenofibric acid. 
The benzhydrol product of the carbonyl reduction of fenofibric acid undergoes 
glucuronidation as well, in order to be excreted in urine. The excretion of 
glucuronosylated products in human occurs mainly via urine (~60%) and the rest 
leaves the organism through feces. In feces it was found that it is excreted fenofibric 
acid and other unidentified polar compounds (Weil et al., 1990). On the contrary, in 
the case of other mammals, as dog and rats, the excretion takes place in the greatest 
degree through the bile (80%) (Caldwell, 1989). 






Figure 3. Reaction scheme of fenofibric acid. UGT= Uridine 5`- diphospho-Glucuronosyl 















3. AIM OF THE WORK 
 
The aims of the present diploma thesis are: 
 To examine the optimal extraction method for the reduced metabolite of 
fenofibric acid. 
 To compare the activity of two human liver fractions, i.e. cytosol and 
microsomes, toward reduction of fenofibric acid. 
 To investigate the ability of a variety of cytosolic enzymes to reduce fenofibric 
acid. 
 To determine the enzymatic activity of the most active cytosolic enzymes at a 
various concentrations of fenofibric acid. 
 To examine the influence of methanol on the reduction activity of cytosol 
toward fenofibric acid. 















4. MATERIALS  
4.1 Chemicals 
Acetonitrile     Sigma-Aldrich, St. Luis, USA 
Ammonia 23-25%    Penta, Czech Republic 
Distilled water Department of Biochemistry,  
Faculty of Pharmacy, Hradec Kralove 
Ethyl acetate     Sigma-Aldrich, St. Luis, USA 
Fenofibic Acid   Aldrich Chemistry, Milwaukee, USA 
Glucose-6- Phosphate (6mM)   Sigma-Aldrich, St. Luis, USA 
Glucose-6-Phosphate dehydrogenase(35U/I) (from yeast), Boehringer Mannheim, 
(GmBH) Germany 
Hydrochloric acid    Penta, Czech Republic  
Methanol     Fluka analytical, Sigma-Aldrich, USA 
NADP
+ 
(0,8mM) SERVA, Germany 
n- Hexane     Merck 
 
4.2 Buffers and Solutions 
Na- phosphate buffer 0,1M Na2HPO4, pH=7,4 
The phosphate solution was prepared by mixing solutions of 0.1M Na2HPO4.12H2O 




 and glucose-6-phosphate were weighted out and diluted in MgCl2 and Na-
phosphate buffer. In the end, glucose-6-phosphate dehydrogenase was added. For the 




Table 4. NADPH Regeneration System recipe.  
Substance 10 samples Final amount 
NADP
+
 2mg 0.8mM 
Glucose-6-phosphate 6mg 6mM 
MgCl2 100μl 3mM 
Na-phosphate buffer 100μl  
Glucose-6-phosphate dehydrogenase 5μl 35U/1 sample 
MgCl2  (3mM) MgCl.6 H2O 1.017g/50ml H2O 
0.1 M Na-phosphate buffer pH=7.4 see above 
 
Mobile Phase: 






Cytosol      c = 8μg/μl, c = 10μg/μl 
Microsomes      c = 3.90μg/μl, c = 5μg/μl 
The solutions of purified recombinant enzymes prepared at the Department of 
Biochemistry, Faculty of Pharmacy, Hradec Kralove 
AKR1A1      c = 1.90mg/ml (09/11/2012) 
AKR1B1      c = 1.25mg/ml (31/03/2014) 
AKR1B1 BB (bugbuster)    c = 0.56mg/ml (09/01/2015) 
AKR1B1 SON (sonication)    c = 0.79mg/ml (09/01/2015) 
AKR1B10      c = 1.61mg/ml (08/03/2012) 
AKR1C1      c = 1.84mg/ml (19/12/2013) 
AKR1C2      c = 1.96mg/ml (12/12/2013) 
AKR1C3      c = 1.92mg/ml (06/02/2014) 
AKR1C4      c = 1.77mg/ml (06/08/2013) 
CBR1       c = 2.11mg/ml (28/03/2014) 






Analytical balance    Sartorius / Scaliter SBC22 
Centrifuges     Mini spin plus, Eppendorf, Germany 
       Biofuge Stratos, Herdeus HIM2812, 
      Kendro Laboratory Product, Germany 
HPLC column HALO.5
®
, C18, 5μm, 4,6mm X 250mm, 
Advanced Materials Technology, USA 
Concentrator     5301, Eppendorf, Germany 
Disposable hypodermic needle   Braun (0.90 x 40 mm) 
HPLC      Shimadzu
®
 UFLC CTO-20AC, Japan 
Incubator     Broer, Mixing Block MB102 
      Thermomixer compact, Eppendorf 
Microtubes      Eppendorf  
Multipipettes     Eppendorf  
pH meter     Sigma Instruments, India 
Pipettes     Eppendorf, Biohit 
Syringe filter PTFE membrane Polypropylene  
(4mm, 0.2μm) Whatmann 
Syringe without needle   1mL, Terumo, Philippines 
Ultrasonic bath    Manufacture Expert 







5.1 Preparation of liver fractions 
The subcellular liver fractions (cytosol and microsomes) that were used in the present 
work were prepared corresponding to the Czech legislation and have been obtained by 
Cadaver Donor Program of the Transplant Center of the Faculty of Medicine in 
Hradec Kralove (Czech Republic). The tissue samples were prepared in order to 
obtain the subcellular fraction as it has been already described (Skarydova et al., 
2013).The liver fractions were used at concentrations 100μg/20μl and 50 μg/ 20μl. 
Dilutions from the stock solution were formed in Na-phosphate buffer, pH 7.4, and 
the total amount of the liver fractions added to each reaction mixture was 20μl. 
 
5.2 Preparation of recombinant enzymes 
The preparation of the forms of the recombinant cytosolic enzymes that were tested in 
the present diploma thesis, i.e. AKR1A1, AKR1B1, AKR1B10, AKR1C1, AKR1C2, 
AKR1C3, AKR1C4, CBR1 and CBR3, were obtained by expression in Escherichia 
coli, by the means of the standard techniques as mentioned (Skarydova et al., 2014). 
The recombinant enzymes were used at concentration 20μg/20μl. Dilution from the 
stock solution was formed in Na-phosphate buffer pH 7.4, and the total amount of 
added to each reaction mixture was 20μl.  
 
5.3 Incubation 
Incubation procedure is necessary in order to investigate the enzymatic activity, and 
evaluate the specific activity. In any case, a variety of concentration of fenofibric acid 
was prepared (1mM, 2mM, 3mM, 5mM, 7mM, and 10mM) by dilution of stock 
solution (50mM in methanol) with 0.1 M Na-phosphate buffer pH=7.4. Fraction/ 
enzymes were also diluted to final amount of protein (20, 50, or 100μg in 20µl) with 
0.1 M Na-phosphate buffer pH=7.4. NADPH regeneration system was always 
prepared fresh according to the number of tested samples (see composition in Buffers 
and Solutions). The microtubes were placed into the ice, and the solutions were added 
in the following order: 0.1 M Na-phosphate buffer pH=7.4, NADPH regeneration 




centrifuged down in centrifuge. Final volume of reaction mixture including the 
substrate was 100μl, as shown in Table 5. 
Table 5. Composition of reaction mixture 
Solution Volume [µl] 
0.1M Na-phosphate buffer (pH=7.4) 50 
NADPH Regeneration system 20 
Enzyme/ fraction/ phosphate buffer 20 
Fenofibric acid 10 
Final volume: 100μl 
 
Thermo block was set to the temperature of 37
o
C. Pre-incubation of reaction mixture 
was performed for 5 minutes. Reaction was started by addition of fenofibric acid, and 
stopped after 30 minutes by addition of 40μl ammonium solution (25%), or 1M HCl, 
and tubes were transferred to the ice. If needed, 30μl of internal standard was added. 
Then, extraction was performed as described below. Every incubation was performed 
at least in three independent determinations for each experiment. 
 
5.4 Preparation of samples 
5.4.1 Optimization of Extraction methods  
After stopping the enzymatic reaction, ethyl acetate was added and either one or two 
fold extraction was performed. In case of one fold extraction, 1000μl of ethyl acetate 
was added in each tube. The tubes were shaken for 15 minutes using shaker. Then, 
they were centrifuged for 2 minutes at 13.000 rpm. The upper organic phase was 
transferred into the new eppendorf tubes and the samples were evaporated to dryness 
into the concentrator under vacuum at 30
o
C. In case of the two fold extraction, after 
the organic upper layer was transferred to a new tube, the same procedure was 
repeated with the down phase. So, in the end the extraction was completed by 1000μl 




mixture of n-hexane and ethyl acetate (90:10, v/v) followed by the same procedure as 
in the case of ethyl acetate. The filtration method was also investigated instead of the 
liquid-liquid extraction. In this case, the incubation reaction was ended by addition of 
300μl of ice-cold methanol , 30μl IS was added and the samples were stored in ice for 
10 minutes. Then, samples were centrifuged at 10.000g at 4
o
C for 15 minutes. Finally, 
they were filtered through a filter by the use of syringe, transferred in fresh tubes and 
evaporated in vacuum at 30
o
C for approximately 3 hours. 
5.4.2 Preparation of samples for HPLC analysis 
The residue of the examined samples, was diluted in 200ul of mobile phase. Solutions 
were allowed to dissolve in the ultrasonic bath, mixed by vortex and shortly 
centrifuged, and finally transferred to vials with 400μl inserts. 
 
5.5 High performance liquid chromatography 
The HPLC machine was SHIMADZU
®
 and the column was HALO.5
®
 C18, of size 
5μm, length 250 and diameter 4mm. The analysis was performed at isocratic flow 
with the mobile phase as stated before. The flow rate of the pump was 1 ml/min, the 
pressure was 110-111 bars, and the column was kept at the temperature 25
o
C. UV-
VIS detection was performed at 229nm, 288nm at and 292nm, with elution time 5 
minutes, 8.55 minutes and 10.720 minutes for detection of reduced fenofibric acid, 
fenofibric acid and internal standard, respectively. The duration of analysis was 15 
minutes per tested sample. Peaks, areas and graphs of the analysis were evaluated 
using the LC solution software by SHIMADZU
®
. 
The samples were injected automatically into the chromatographic system in the 
volume of 100μl. Degasser is responsible for removing the gas from the mobiles 
phase, while the pump was set to provide it in the column constantly by 1 ml/min. The 
oven was set to maintain the proper temperature. The photodiode-array detector was 
used to monitor the signal of the eluent. 
All details regarding the analytical HPLC method as well as the selection of internal 
standard (IS) and chromatographic conditions will be presented in prepared paper by 




The HPLC provide us the opportunity of both qualitative and quantitative analysis. In 
this case it allowed us to examine if the enzymes had reduced the fenofibric acid to its 
metabolic product, but also to calculate the amount of that product. 









Autosampler Column oven 






5.6 Determination of enzyme kinetics 
Cytosol, microsomes and the carbonyl-reducing enzymes that exhibited reductase 
activity toward fenofibric acid were used to determine the kinetic parameters. 
Incubations were performed as previously described with a final concentration of 
fenofibric acid in the range of 100 to 1500 μM. The apparent kinetic parameters were 
calculated using GraphPad Prism ® 6.0 computer software. The formation of reduced 
fenofibric acid was fitted to both the Michaelis-Menten hyperbola and allosteric 
sigmoidal kinetic models. The best-fit model was determined based on the ranking of 
the coefficient of determination (R
2
) and Hill slope (h). Enzymatic activity was 
expressed as the specific enzyme activity that represents pmol or nmol of formed 
reduced fenofibric acid per mg of protein in 1 min. Internal clearance (CLint) 
represents enzymatic efficiency and is defined as Vmax/Km. The values were given as 



















6. RESULTS AND DISCUSSION  
6.1 High performance liquid chromatography 
The detection of the reductive product was achieved by the use of the standard of 
reduced fenofibric acid (10
-5
 M). The volume of injected samples and standards was 
100 µl. 
 
Graph 1. Representative chromatogram of the standard of reduced fenofibric acid. 
 
The area of the standard of reduced fenofibric acid was around 923700 corresponding 
to 320.77ng. Elution time of reduced fenofibric acid was 5.000 minutes (±- 0.200) as 
depicted in Graph 1. 
  































Graph 2 represents the internal standard (IS) that was used in these analyses. The 
concentration of this standard injected was again 10
-5
 M and the detection was 
achieved at 292nm with elution time at 10.720 minutes (±0.400). 
 
  
Graph 2. Representative chromatogram of standard of IS. 
 
Finally the standard of our investigated drug, fenofibric acid (injected at the 
concentration 10
-5
 M) was detected at 288nm at 8.55 minutes (±0.300). Graph 3 
shows the peak of fenofibric acid. 
 
Graph 3. Representative chromatogram of standard of fenofibric acid. 
























































The following graphs belong to the examined cytosolic fraction and cytosolic 
enzymes, which were analyzed for their ability to reduce fenofibric acid. 
 
Graph 4. Representative chromatograph of reduced fenofibric acid by cytosol at 500μΜ FA. 
Graph 4 shows the area of reduced fenofibric acid after incubation of cytosol with 
500μM fenofibric acid. The depicted area is 5896, that corresponds to 2.49 ng of 
reduced fenofibric acid. 
 
Graph 5. Representative chromatograph of reduced fenofibric acid by CBR1 at 300μM FA. 
Graph 5 represents the area (3225689) of the chromatograph for the analysis of 
reduction of fenofibric acid (300μM) by CBR1. This area corresponds to 1365.5ng of 
produced reduced fenofibric acid. 
 

























































Finally, Graph 6 shows a peak with the area 6709 for reduction of fenofibric acid 
(100μM) by AKR1C3 that corresponds to 2.84ng of reduced fenofibric acid. 
 
Graph 6. Representative chromatograph of reduced fenofibric acid, by AKR1C3 at 100μM 
FA. 
 
The repetition of experiment helped us to investigate a problem with the evaluation of 
the HPLC analysis for enzyme AKR1C3. It was found that in many cases separation 
of the reduced fenofibric acid was not clear. In many cases there were present “peak 
tailing” as shown in the Graph 6, or “shoulder peaks”. The examination was repeated 
again after washing of column and pumps of the HPLC, but these problems remained. 
Worth saying is that this situation concerned only the enzyme AKR1C3. Since 
contamination was excluded, suggestions for avoiding this poor chromatography 

































6.2 Optimization of extraction 
In this test, we examined the optimal extraction method. The test of the extraction was 
performed using standard incubation with fenofibric acid at two concentrations (100 
and 500 μM) and 38,4μg of the enzyme AKR1C3. The methods used for extraction 
were filtration, extraction by ethyl acetate or by mixture of n-hexane: ethyl acetate 
(90:10, v/v). In each method, 10 μg of internal standard were added after the 
enzymatic reaction was stopped. The efficiency of extraction method was calculated 
for the internal standard. 
Table 6. Extraction efficiency of internal standard using various extraction methods. 
F= filtration, e= one fold extraction with ethyl acetate, nhe= extraction with n-hexane:ethyl 
acetate (90:10), FA = fenofibric acid, redFA = reduced fenofibric acid. 
According to the results of the extraction efficiency of internal standard, as shown in 
the Table 6, the most efficient extraction at the lower concentration of fenofibric acid 
was one fold extraction with ethyl acetate (extraction efficiency 109%), followed by 
extraction with the mixture of n-hexan and ethyl acetate (90:10, v/v) (extraction 
efficiency 98.2%). On the other hand, at higher concentration of fenofibric acid, the 
extraction efficiency was slightly higher with the mixture n-hexan and ethyl acetate 
(extraction efficiency 96%) than with ethyl acetate (extraction efficiency 92.2%). The 
extraction efficiency of internal standard using filtration method was at both 
concentration of fenofibric acid almost zero (0.62% and 0.58%). Moreover, the 
analyzed amount of both fenofibric acid and reduced fenofibric acid was very low or 











C3-1/f 100 0 25.8 61.2 0.6 (±0.05) 
C3-2/f 500 0 148.1 57.9 0.6 (±0.03) 
C3-1/e 100 3.07 2395.4 10814.1 109.0 (±11.7) 
C3-2/e 500 5.51 12870.3 9149.4 92.2 (±1.9) 
C3-1/nhe 100 4.62 2244.1 9743.9 98.2 (±1.6) 




even zero, respectively. Therefore, filtration is not an appropriate method for the 
extraction of the fenofibric acid and its metabolite or for internal standard. 
Taking a further look at the facts shown in the Table 6, can be observed that the 
amount of the produced reduced fenofibric acid in case of 100μM of fenofibric acid is 
higher using the extraction method with mixture of n-hexane and ethyl acetate (90:10, 
v/v) than by ethyl acetate (4.62 ng vs. 3.07, respectively). For the higher 
concentration, 500μM fenofibric acid, the amount of the reduced product is slightly 
higher in the extraction method by ethyl acetate than mixture of n-hexane and ethyl 
acetate (5.51 vs. 4.72 ng reduced fenofibric acid, respectively). The amount of 
extracted fenofibric acid was somehow higher using extraction by ethyl acetate than 
mixture of n-hexane and ethyl acetate at both concentrations of fenofibric acid. 
Correspondingly, as represents Table 7, calculated specific activity for the samples 
shows that the specific of the samples extracted by mixture of n-hexane and ethyl 
acetate was higher than ethyl acetate extraction (12.5 vs. 8.3 pmol/min/mg, 
respectively). However, the specific activity for the second concentration, 500μM 
fenofibric acid, was greater using the ethyl acetate extraction method (15.00 vs. 12.7 
pmol/min/mg).  












Ethyl acetate HCl 100 8.3 
Ethyl acetate HCl 500 15.0 
n-Hexane:Ethyl ac.(90:10) HCl 100 12.5 
n-Hexane:Ethyl ac.(90:10) HCl 500 12.7 
Filtration MetOH 100 0.0 
Filtration MetOH 500 0.0 
FA = fenofibric acid 
Because the extraction efficiency by ethyl acetate and the mixture of n-hexane and 
ethyl acetate was comparable for all tested compounds but n-hexane is more toxic 





The following part of the search for the optimal extraction method was to compare 
extraction efficiency of one fold and two fold extraction with ethyl acetate. Again the 
examined enzyme was AKR1C3, but in amount of 20μg in 100μl of the reaction 
mixture. The extraction efficiency of both one and two fold ethyl acetate extraction 
was calculated for fenofibric acid using the method where fenofibric acid was added 
into the incubation mixture after the reaction was terminated by the addition of the 
HCl, which was considered to provide 100% of fenofibric acid. The following Table 8 
contains the results. 
 
Table 8. Extraction efficiency of fenofibric acid. 
Sample Final conc. 
FA[μM] 
Amount of FA 
detected (ng) 
Extraction efficiency of 
FA (%) 
C3-1/e 100 2834.7 93.2 (±3.67) 
C3-2/e 500 20121.1 103.7 (±2.54) 
C3-1/ee 100 2787.5 91.6 (±1.13) 
C3-2/ee 500 17944.3 92.4 (±6.15) 
FA was added after the termination of the reaction, e=one fold extraction with ethyl acetate, 
ee=two fold extraction with ethyl acetate, FA = fenofibric acid.  
 
At both tested concentrations of the drug, the highest extraction efficiency of 
fenofibric was with one fold extraction with ethyl acetate. Interestingly, the extraction 
efficiency of one fold extraction was higher at 500μM fenofibric acid than at 100μM 
fenofibric acid, giving the extraction efficiency 103.7% and 93.2%, respectively. The 
two fold ethyl acetate extraction at both concentrations of fenofibric acid showed 
similar extraction efficiency with values 91.6 % and 92.4% at lower and higher 




In the Table 9 are written the specific activities calculated for both extraction 
methods. 
Table 9. Specific activity for reduction of fenofibric acid using various extraction methods. 
Extraction Reaction 
stopped 








1x ethyl acetate HCl 100 35.9 
1x ethyl acetate HCl 500 67.4 
2x ethyl acetate HCl 100 18.4 
2x ethyl acetate HCl 500 21.2 
FA = fenofibric acid 
 
All the extraction methods and their percentage efficiency results of are shown in the 
Graph 7. 
 
Graph 7. Results of % extraction efficiency of all tested methods. Ethyl acetate I and n-he – 
extraction efficiency was calculated for internal standard. Ethyl acetate II and 2x ethyl acetate 
I - – extraction efficiency was calculated for fenofibric acid. 
According to extraction tests that were performed using the enzyme AKR1C3, the 























concetration of fenofibric acid 









6.3 Calibration curve 
For the quantification of the metabolized product of the fenofibric acid by the tested 
enzymes, i.e. reduced fenofibric acid, it was used the calibration curve. For the 
construction of calibration curve eight concentrations of fenofibric acid in the range of 
0.05 - 10.00 μΜ were used. In detail, the concentrations were: 0.00002μg/μl, 
0.00003μg/μl, 0.00016μg/μl, 0.00032μg/μl, 0.00160μg/μl, 0.00321μg/μl, 
0.01604μg/μl, and 0.03208μg/μl. The volume injected was 100μl. 
 
Graph 8. Calibration curve of reduced fenofibric acid 
Important parameter that characterizes the calibration curve is the linearity of the 
method, which arises from the value of the R
2
. The closer to the 1 the R
2 
is, the better 
the linearity. In this case the R
2
 equals to 0.9997. This shows that the obtained 
calibration curve is accurate and can be used for calculations. 
 
6.4 Test of influence of methanol 
In order to achieve complete dissolution of fenofibric acid, the stock solution was 
prepared in methanol. Methanol is an organic solvent that is toxic and can inhibit the 
activity of many enzymes (Vuppugalla et al., 2007; Behere et al., 2014). The final 
amount of methanol in the incubation mixture was in the range of 0.2 to 3%. At the 
concentration of fenofibric acid of 500μM, the amount of methanol was 1%. 
Because methanol can influence the activity of the enzymes (Vuppugalla et al., 2007; 
Dayanididhi et al., 2014), the influence of increasing amount of methanol (0.5, 1.0, 
y = 2.362.170,8222x 















2.0, 3.0 and 5.0%) on the reducing activity of cytosol was tested. For this 
examination, samples were prepared with 50μg of cytosolic fraction and 500μM 
fenofibric acid and different amount of methanol. The experiment was repeated four 
times. The values were then edited in Microsoft Office EXCEL 2007, to calculate the 
specific activity of the cytosol, and ANOVA was applied to test if there is significant 
difference between the samples of different concentrations of methanol. Results are 
presented in Table 10. 
 
Table 10. The influence of methanol on specific activity. 










50 500 0.5 7.16 (±0.82) 
50 500 1.0 7.18 (±0.85) 
50 500 2.0 8.83 (±0.85) 
50 500 3.0 9.91 (±1.04) 
50 500 5.0 7.55 (±0.77) 
 
The values of the specific activity of cytosol in samples with different concentrations 
of methanol were examined with ANOVA (see Table 11), and the ρ value was equal 
to 0.01. Since ρ< 0.05, there were no statistically significant differences between 
group means. To the current test it means that at the concentration of 500μM 
fenofibric acid the amount of methanol in percentage from 0.5 to 5.0 % does not 
influence the enzymatic activity. 
Table 11. ANOVA calculations  
Source of Variation SS df MS F P-value F crit 
Between Groups 22,28087 4 5,570218 4,817631 0,010622 3,055568 
Within Groups 17,34323 15 1,156215 
   
       Total 39,6241 19 




6.5 Screening of liver fractions and enzymes 
The purpose of the current test was to investigate cytosol, microsomes and a variety 
of cytosolic enzymes for their ability to reduce fenofibric acid. Liver fractions were 
added at the final concentrations 100 and 50 μg/100μl, and fractions of cytosolic 
enzymes at 20μg/100μl. Reaction was stopped in all incubations by HCl, and in many 
cases also by NH3. All samples were extracted once by ethyl acetate. Findings of the 
screening are shown in the following Table 12. 
Both cytosol and microsomes exhibited reductase activity toward fenofibric acid. At 
the lower concentration of fenofibric acid, the activity of cytosol was more than two 
times higher than that of microsomes. On the contrary, at concentration 500μM of 
fenofibric acid, the activity of cytosol was slightly higher than that of microsomes. 
Table 12 indicates where the reaction was stopped by NH3 and where by HCl. 
However, HCl was better reagent for termination of the reaction and was used in all 
following experiments. 
The most active among all the enzymes was CBR1, an enzyme from the SDR 
superfamily, followed by an AKR enzyme, AKR1C3. Significant activity was also 
exhibited by the AKR enzymes AKR1C1, AKR1C2 and AKR1B1. Moreover, slight 
activity was detected with AKR1C4 but only at the lower concentration of fenofibric 
acid. On the other hand, the enzymes AKR1B10, AKR1A1 and CBR3 did not show 
any reductase activity toward fenofibric acid. 
Taken together, the order of the reducing activity of the recombinant cytosolic 
enzymes was as follows: CBR1>>AKR1C3>AKR1C2≥AKR1C1>AKR1C4. In 
addition, the order of the reducing activity in human liver subcellular fraction was 
microsomes>cytosol. 
The highest reducing activity of the recombinant enzymes tested was found for 
CBR1. CBR1 showed higher activity compared to cytosol and microsomes and its 
activity was 70 times higher than that of the second most active enzyme, AKR1C3. 
Therefore, CBR1 may be suggested as the main cytosolic enzyme responsible for the 





















Cytosol  100 100 5,00 NH3 Ethyl acetate 
  100 500 25,39 NH3 Ethyl acetate 
Pooled 50 100 25,94 HCl Ethyl acetate 
Pooled 50 500 47,31 HCl Ethyl acetate 
Microsomes 100 100 2,75 NH3 Ethyl acetate 
  100 500 6,72 NH3 Ethyl acetate 
Pooled 50 100 11,39 HCl Ethyl acetate 
Pooled 50 500 43,58 HCl Ethyl acetate 
CBR1 20 100 13,05 NH3 Ethyl acetate 
  20 500 60,14 NH3 Ethyl acetate 
  42,2 100 2780,30 HCl Ethyl acetate 
  42,2 500 12200,90 HCl Ethyl acetate 
AKR1C3 20 100 6,61 NH3 Ethyl acetate 
  20 500 not determined NH3 Ethyl acetate 
  20 100 35,86 HCl Ethyl acetate 
  20 500 67,31 HCl Ethyl acetate 
AKR1C1 20 100 3,09 NH3 Ethyl acetate 
  20 500 3,54 NH3 Ethyl acetate 
  36,8 100 2,90 HCl Ethyl acetate 
  36,8 500 6,20 HCl Ethyl acetate 
AKR1C2 20 100 3,34 NH3 Ethyl acetate 
  20 500 3,95 NH3 Ethyl acetate 
  39,2 100 5,10 HCl Ethyl acetate 
  39,2 500 6,50 HCl Ethyl acetate 
AKR1B1 20 100 0,00 HCl Ethyl acetate 
  20 500 1,32 HCl Ethyl acetate 
  25 100 6,00 HCl Ethyl acetate 
  25 500 9,00 HCl Ethyl acetate 
AKR1B10 20 100 0 HCl Ethyl acetate 
  20 500 0 HCl Ethyl acetate 
AKR1A1 20 100 0 NH3 Ethyl acetate 
  20 500 0 NH3 Ethyl acetate 
AKR1C4 20 100 2,76 NH3 Ethyl acetate 
  20 500 0 NH3 Ethyl acetate 
CBR3 20 100 0 NH3 Ethyl acetate 




Although AKRB1 was active on reduction of fenofibric acid, its activity was 7-times 
lower than the activity of the most active AKR enzyme, AKR1C3. Other AKR 
enzymes, AKR1C1 and AKR1C2 had similar activity toward fenofibric acid 
reduction but even lower than AKR1B1. Their activity was 10-times lower than that 
of AKR1C3. Additionally, AKR1C4 showed the lowest activity of all tested enzymes 
and therefore, this enzyme was not involved in further experiments. 
It was also performed screening test for the enzyme AKR1B1 at the concentration of 
fenofibric acid of 500μM, in order to compare the activity of recombinant enzymes 
prepared by two different approaches. The one approach involved using Bug Buster 
for release of the overexpressed protein, and the second one sonication. As it is 
depicted in Table 13, the sample obtained from bug buster had higher reducing 
activity (59.87 vs. 48.46 pmol/min/mg). 













AKR1B1 20 500 HCl Ethyl acetate 46.29 ±16.10 
AKR1B1_BB 16.8 500 HCl Ethyl acetate 59.87±15.45 
AKAR1BI_SON 16.8 500 HCl Ethyl acetate 48.46±8.93 
BB= bug buster, SON= sonication 
 
6.6 Enzyme kinetics 
After the initial screening of the subcellular fractions and the cytosolic enzymes it was 
determined the enzyme kinetics. For this purpose, it was measured the velocity of the 
reductase activity of the enzymes at various concentration of the substrate. In 
particular, it was measured at 7 concentrations of fenofibric acid; 100μM, 200μM, 
300 μM, 500μM, 700μM, 1000μM and 15000μM. The incubation was performed with 
optimized conditions, i.e. 20μg of recombinant enzymes or 50μg of subcelullar 
fraction was incubated with fenofibric acid and the reaction was terminated by the 
addition of HCl followed by one fold extraction with ethyl acetate. The amount of 
produced reductive product was determined by the help of HPLC and the specific 




were determined using the GraphPad Prism ® 6.0 computer software, as described in 
Methods. 
The Figure 5 (A-C) presents three measurements that correspond to the kinetic of 
cytosol, since it was repeated in 3 different days and there was significant difference 
between them. While for microsomes, the kinetic was unambiguously fitted to 
Michaelis-Menten, as shown in the Figure 5D. 
  
 
Figure 5. Kinetics of fenofibric acid reduction by human liver cytosol (A-C) and microsomes 
(D). A is according to Michaelis-Menten, B and C according to allosteric sigmoidal kinetics, 
D kinetics of microsomes according to Michaelis-Menten equation. 
Parameters of the kinetics of the human liver fractions are written in the Table 14. 
Table 14. Kinetic parameters of human subcellular liver fractions. 
 Vmax 
[pmol/mg/min] 






 CLint  
[μl/mg/min] 
Model 
 C I 109±8.192 410.00±69.09  0.9307 0.265 M-M 
C II ~597372 ~98246±1.74x108 2.087±0.670 0.9416  Allost. 
C III 105±20.84 1020±149.6 3.464±0.866 0.9228 0.103 Allost. 






C = cytosol, M = microsomes, Vmax is maximum enzyme activity, Km Michaelis constant for 
Michaelis-Menten (M-M) equation, and h is the Hill slope, that characterizes the steepness of 
the curve and presence of cooperativity. 
Comparing the measurements according to Michaelis-Menten equation, we can 
assume that Vmax, expressed as specific activity, of the microsomes is 42.1%  greater 
than that of cytosol (154.9 vs. 109 pmol/mg/min). However, Michaelis constant for 
microsomes is 150% higher than that for cytosol (1027 vs. 410 μM), meaning the 
greater affinity of cytosol over microsomes . 
On the other hand, in the second measurement of cytosol kinetics, there was found 
better fit for allosteric sigmoidal equation. This can lead us to a though that probably, 
it can occur difference in kinetics between the individuals (Takahashi et al., 2008). It 
should be noted, that in all three kinetic measurements, it was used the same stock 
solution of cytosol. The tested cytosol was pooled and obtained from liver of eight 
different people. 
Another parameter taken in consideration is the internal clearance CLint expressed as 
Vmax/Km [l/mg proteins/min]. Comparing the Clint derived from the Michaelis Menten 
equation of cytosol and microsomes, we observe that the metabolism in cytosol is  
70% higher than in microsomes (0.265 vs. 0.151 μl/mg/min). 
Figure 6 and Table 15 show the kinetics of the enzymes that exhibited the highest 
specific activity during the screening experiment. Apart from the enzyme AKR1C3 
for which the number of independent determinations was 8, for the rest of enzymes 
were performed 4 determinations. The selection of the equation of the enzymatic 






Figure 6. Kinetics of the fenofibric acid reduction catalyzed by the recombinant cytosolic 
enzymes. A) CBR1 according to Michaelis-Menten, B) AKR1C3 according to Michaelis-
Menten, C) AKR1B1 allosteric sigmoidal kinetic, D) AKR1B1 according to Michaelis-






Table 15. Kinetic parameters of recombinant cytosolic enzymes. 
CBR1 and AKR1C3 were fitted to Michaelis-Menten (M-M) kinetics, AKR1B1 to both 
allosteric sigmoidal and Michaelis-Menten kinetics, AKR1C1 and AKR1C2 to allosteric 
sigmoidal kinetics. Vmax is maximum enzyme activity, Km Michaelis constant for Michaelis-
Menten equation, K half for allosteric sigmoidal and h is the Hill slope, that characterizes the 
steepness of the curve and presence of cooperativity. 
The enzymatic activity of the enzymes CBR1, AKR1C3 and AKR1B1 fitted to 
Michaelis-Menten equation. As shown in Table 15, the enzyme CBR1 is clearly the 
most active enzyme toward fenofibric acid reduction. Vmax expressing the enzymatic 
activity of CBR1 is almost 400 times higher than that of AKR1C3, and 100 times 
higher than that of AKR1B1. Considering Michaelis constant, affinity of CBR1 and 
AKR1C3 is very similar and both have almost 10 times higher affinity than AKR1B1. 
Nevertheless, the enzyme AKR1B1 fitted as well allosteric sigmoidal model of 
kinetics along with the enzymes AKR1C1 and AKR1C2. This result suggests the 
thought of the existence of multiple ligand binding sites. Hill coefficient reflects the 
degree of cooperativity among those binding sites. Therefore, AKR1C2 has a 
maximum number of interacting sites. 
Additionally, the highest enzymatic efficiency expressed as CLint is for CBR1 355 
times higher than that for AKR1C3 (85.97 vs. 0.242 μl/mg/min). Concerning the rest 













CBR1 31183±979 362.7±27.13  0.9826 85.974 M-M 
AKR1C3 77.56±4.332 320.5±47.5  0.8100 0.242 M-M 
AKR1B1 296.7±68.81 3316±1007  0.9683 0.089 M-M 
AKR1B1 128.7±17.85 860.6±179.4 1.477±
0.1653 
0.9783 0.150 Allost. 
AKR1C1 312.6±158.8 1629±941.2 1.625±
0.3342 
0.9539 0.192 Allost. 
AKR1C2 81.89±2.294 357.2±13.48 3.895±
0.4197 




AKR1C2 is similar as that for AKR1C3 (0.242 vs. 0.229 μl/mg/min). CLint of 
AKR1C1 is only slightly lower than that of AKR1C3 (0.242 vs. 0.192 μl/mg/min). 
Finally, AKR1B1 shows the lowest CLint, reaching almost 1000 times lower value 
than that of CBR1 (85.97 vs. 0.089 μl/mg/min). 
So the order of the activity of the carbonyl-reducing enzymes toward fenofibric acid 
could be the following, from highest to lowest: 
CBR1>>AKR1C3>AKR1C2>AKR1C1>AKR1B1. 
Up to now, examination of the metabolism of fenofibric acid has been taken place for 
rats, dogs, guinea pigs, cynomolgus monkey (Weil et al., 1988; Cornu-Chagnon, 
1995; Liu et al., 2009a; Liu et al., 2009b; Yang et al., 2013). 
In 1988, Weil et al. demonstrated that reduced fenofibric acid was the major 
elimination metabolite of fenofibrate excreted via urine, as a result of carbonyl 
reduction in rat, guinea pig and dog (Weil et al., 1988). Caldwell published in 1989 
the biochemical pharmacology of fenofibrate, reporting the carbonyl reduction of 
fenofibric acid to its reduced metabolite in humans. It was also pointed the important 
quantitative difference in the metabolism of fenofibric acid among species (Caldwell, 
1989). 
In 1995, Cornu-Chagnon et al. while investigating primary cultured hepatocytes 
assessing peroxisomal β-oxidation by cyanide-insensitive palmitoyl CoA for 
metabolism of fenofibrate among other, also identified after a 24hours metabolization 
the formation of reduced fenofibric acid after addition of fenofibric acid. They also 
reported ester glucuronides of both fenofibric and reduced fenofibric acid (Cornu- 
Chagnon et al., 1995). 
Unique additional findings of metabolites occurred so far in cynomolgus monkeys 
species, in which fenofibric and reduced fenofibric acid are conjugated with taurine 
(Liu et al., 2009). Those metabolites where also identified in Sprague-Dawley rats 
after plasma and urine analysis (Liu et al., 2009).  
In vitro and in vivo study of the metabolism of fenofibric acid in beagle dog 
hepatocytes concluded that fenofibrate is more metabolized to reduced fenofibric acid 




The Table 16 concludes all those data concerning the metabolism of fenofibrate. 
Table 16. Summary of fenofibrate metabolites in different species. 
Adapted from Yang et al., 2013. 
Metabolites Human Monkey Guinea Pig Rat Dog 




FA √ √ √ √ √ √ √ 
RFA √ √ √ √ √ √ √ 
FAEG √ √ √ √ √ √ √ 
RFAEG √ √ √ √ √ √ √ 
FAT  √  √ √ √ √ 
RFAT  √  √ √ √ √ 
B  √  √ √ √ √ 
X  √  √ √ √ √ 
AR  √   √   
A √      √ 
FA=fenofibric acid, RFA= reduced fenofibric acid, FAEG= fenofibric acid ester glucuronide, 
RFAEG= reduced fenofibric acid ester glucuronide, FAT= fenofibric acid taurine, RFAT = 
reduced FAT, metabolite B= 4-chloro-4’-isopropoxybenzophenone, ,compound X= 2-[4-(4-
chloro-benzoyl)-phenoxy]-2-methylpropionic acid methyl ester, compound A= 4-chloro-4_-
hydroxybenzophenone, compound AR= reduced compound. 
 
Information for biotransformation of reduced fenofibric acid, do not exist further than 
the previous ones, taking in consideration that fenofibrate is rapidly hydrolyzed by 
esterases to fenofibric acid.  
Another notable information about metabolism of fenofibric acid is the fact that 
fenofibric acid was initially reported as substrate for reduction by cytochrome P450 
isoforms but it has been lately proven false (Prueksaritanont et al., 2002; Whitfield et 
al., 2011).  
The finding of CBR1 as an efficient reducing enzyme toward fenofibric acid gives us 
the opportunity to guess and further investigate drug-drug interactions. CBR1 is one 
of the well-studied CREs, which has proofed its participation in many xenobiotic 
biotransformation pathways. E.g., nabumetone has been found to be in vitro reduced 
mainly by CBR1, but in vivo studies demonstrated lower activity than the expected 
results (Skarydova et al., 2013; Malatkova and Wsol, 2014). Benfluron and 




information is of limited importance, though those agents failed to undergo further 
clinical trials. 
Monotherapy of either fenofibric acid or statins is a rational pharmacotherapy for 
managing dyslipidemias. However, in many cases has been discussed a combination 
therapy with both of them. Concerning many fibrate derivatives, this combination 
therapy is contraindicated due to drug-drug interactions, e.g. competing 
glucuronidation by the enzymes UGT1A1 and UGT1A3. However, fenofibric acid 
undergo glucuronidation by enzymes UGT1A9 and UGT2B7 that do not metabolize 
statins. Additionally, fenofibric acid reduction is mediated by other enzymes than 
biotransformation of statins that is mediated through enzyme CYP3A4 (Corsini et al., 
2005). Thus, it is feasible that the biotransformation of fenofibrate by carbonyl-
reducing enzymes from SDR and AKR superfamilies does not lead to interaction with 











Biotransformation of a drug is an important process leading to formation of 
compounds that either initiate or extend the pharmacological activity, or detoxify the 
parent xenobiotic.  
Regarding the hypolipidemic agent fenofibric acid, it has been known that in human 
and other mammalians it is metabolized to reduced fenofibric acid, but without any 
further knowledge for the identity of involved enzymes. In our study it was confirmed 
that fenofibric acid is turned to its reduced metabolite as it undergoes carbonyl 
reduction, a reaction that can be catalyzed in both cytosolic and microsomal 
subcellular fractions. The present study has examined both subcellular liver fractions 
but only cytosolic recombinant enzymes. These cytosolic enzymes were from two 
superfamilies of carbonyl-reducing enzyme, the AKR and SDR superfamily. In 
particular, we found that the greatest enzymatic activity belongs to the SDR enzyme 
CBR1, followed by several AKR enzymes.  
This is for the first time when an enzyme performing reduction of fenofibric acid was 
identified. The determination of the enzymes that are responsible for the metabolism 
of fenofibric acid adds one more important information for understanding the drug-
drug interaction, especially with statins. The present diploma thesis proceeded only as 
an in vitro study. In vivo research will be definitely important because it may shed 
more light to the biotransformation of fenofibric acid and the current findings.  
We believe that our findings stimulate the interest in further examination of the 
metabolism of fenofibric acid by carbonyl-reducing enzymes. Especially, the 
identification of microsomal enzymes responsible for carbonyl reduction of fenofibric 
acid is desirable. Additionally, another interesting area is the investigation of the 
chiral aspects of the production of reduced fenofibric acid by the carbonyl-reducing 
enzymes. Notably, both these directions of fenofibric acid research are in progress, 






8. LIST OF ABBREVIATIONS 
 
11β-HSD   11β-Hydrosteroid dehydrogenase 
AKRs    aldo-keto reductases 
CBRs    carbonyl reductases 
CREs    carbonyl-reducing enzymes 
CYP450   cytochrome P450 
DM II    diabetes mellitus II 
HDL    high-density lipoprotein 
HMG-CoA   3-hydroxy-3-methylglutaryl-coanzyme A 
IS    internal standard 
LDL    low-density lipoprotein 
NAD(P)
+
or NAD(P)H nicotinamide adenine dinucleotide or nicotinamide 
adenine dinucleotide phosphate 
NKK nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone 
PPARα   peroxime proliferator-activator alpha 
PUFAs   polyunsaturated fatty acids 
SDRs    short-chain dehydrogenase reductases 
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